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INTRODUCTION:
Heart disease is the leading cause of death in both the United States and Hawaii. According to the Hawaii State Department of Health, over 1/3 of total deaths in the state are caused by cardiovascular disease, in which approximately 18% (hospital discharges) were associated with heart failure (Balabis et al, 2007) . Many patients with endstage congestive heart failure reach a state where present medical therapy is not adequate to sustain acceptable cardiac function. Though this option is presently not available in Hawaii, an exciting new therapy that is emerging is the use of stem cell procedures (Assmus et al, 2006) . The potential of stem cells for use in cell therapy to treat diseased or damaged organs is very promising due to the unique properties of these cells, namely the capacity for both long-term self-renewal and differentiation into various mature cell types. While it may be ideal to treat different organs or tissues with stem cells of the same type (i.e., treat brain with brain-derived stem cells), in many instances tissue-or organ-specific stem cells have either not yet been identified, or the isolation of these stem cells is impractical. Adipose stem cells (ASC) have recently emerged as one of the most attractive types of stem cells for use in cell therapy (Gimble et al, 2011 ) because they are well characterized, are relatively easily purified, and are much more abundant than many other types of stem cells, including hematopoietic stem cells (HSC).
In our previous research, we specifically tested the relative importance of the HSC component of human bone marrow samples to facilitate repair from induced myocardial infarcts using a human to mouse transplantation model. We found that the degree of recovered cardiac function, as indicated by measurements of left ventricular ejection fraction (LVEF), and repair of damaged cardiac tissue post-induction of infarct, as measured by the reduction in size of the infarct area and the degree of re-vascularization of the infarct zone, positively correlated with the number of HSC in the transplanted sample
In this study, we proposed to examine the potential and mechanism of ASC to treat damaged or diseased heart tissue, by 1) testing whether highly purified human ASC samples perform better at facilitating recovery from induced infarcts than bone marrow derived HSC samples, (2) assess whether cardiac-like progenitors, derived via reprogramming of different types of stem cells, will further enhance the therapeutic potential of stem cell-based methodologies in the treatment of heart disease, and 3), assess whether the delivery of re-programming factors into stem cells using a transposasemediated gene delivery system will enhance the re-programming efficiency of stem cells into towards the cardiac lineage. These results should shed light on how important ASC are with respect to use in cell therapy to treat myocardial infarcts, and may also lead to an improved cell therapy based method, involving the reprogramming of donor cells to a cardiogenic fate prior to transplantation, to treat damaged or diseased heart tissue. The technical objectives are to elucidate the following questions-1) Are ASC a more therapeutically valuable source of stem cells to facilitate recovery from ischemic damage and heart disease in cardiac patients than bone-marrow derived stem cells; 2) Are induced cardiac-like cells, obtained by re-programming stem cells using specific transcriptional regulators, a better source of cells to use in transplantation therapies to treat ischemic damage and heart disease in cardiac patients than untreated stem cells ?; 3) Do 
90% complete
New post doctoral fellow, Phil Davy, is now fully trained and proficient in the processes of i) purifying ASC using fluorescent activated cell sorting (FACS) ii) re-programming ASC towards a cardiogenic fate, and iii) performing the surgical procedure in mice to induce cardiac infarct using left anterior descending artery (LAD) ligation, and the intra-cardiac transplantation of cells. A limited amount of good quality cryo-preserved BM samples has been obtained from the Hawaii Transplant Centre, however we are still awaiting the collection of additional samples. We have been waiting for additional BM samples for ~ 5months, and anticipate receiving an additional donor in the next 1-2 months.
Perform comparative analysis of the effect of BM stem cell and ASC samples on recovery from induced infarcts in the murine transplantation model system 50% complete
The transplantation of equal numbers (200,000) of bone marrow derived stem cells and ASC into severe combined immune deficient (SCID) mice has now been performed (initiated June 2012), and end point analysis of the results has begun. Three cohorts were included in the analysis, 2 receiving either HSC or ASC and 1 sham control group (no stem cells transplanted)(n=12 per group). The procedure, briefly, was to induce infarcts in the SCID mice using the LAD ligation technique, followed immediately by inter-cardiac injection of the stem cell samples directly into the site of infarct. End point analyses will be performed 1 month post-transplantation. Specifically, measurements of left ventricular ejection fraction (as assessed using echocardiography), infarct area, and number of new capillaries (capillaries will be detected by Isolectin B staining and counted) at the site of infarct will be compared between the 2 cohorts using Student's t Test. (2) , the delivery of reprogramming factors into stem cells using a transposase mediated gene delivery system will enhance the re-programming efficiency of stem cells into towards the cardiac lineage.
Complete all data analysis and draft manuscripts to publish results

0% Complete TASK B Test the hypotheses that (1) Cardiac-like progenitors, derived via reprogramming of different types of stem cells, will further enhance the therapeutic potential of stem cellbased methodologies in the treatment of heart disease and
Obtain and/or assemble expression vectors for all transcription factors to test in the stem cell-to-cardiogenic lineage re-programming protocol 100% Complete
The re-programming factor expression vector has now been assembled and tested. Specifically, we sub-cloned cDNAs encoding the cardiogenic re-programming factors Nkx2.5, Gata4, Mef2C and Tbx5 into the Piggy Bac transposase-based delivery expression vector, with the help of Dr. Moisyadi. Correct assembly of the vector was confirmed by DNA sequence analysis. The vector was then transfected into the ASC cells to verify, 48 hours post-transfection, that the re-programming factors were being expressed as predicted (based on RT-PCR analysis).
Optimize transduction and re-programming of BM stem cell (HSC) and ASC samples with the lentiviral and transposase-based system for stable gene expression in mammalian cells 90% complete
Optimization of re-programming of ASC cells is complete. For optimization of delivery of the re-programming vector, we tried both the Extreme Gene lipofection method (a technique to introduce DNA into cells using lipid vesicles which can easily merge with the cell membrane), electroporation (a technique where cells are briefly exposed to an electrical field which increases the permeability of the cell membrane to allow DNA to get into the cell), and Amaxa transfection method (which combines features of both lipofection and electroporation) to deliver the re-programming vector to ASC, and found that the Amaxa method was substantially superior in efficiency (>50% cells were transfected with Amaxa, as compared to 10% and <1% with lipofection and electroporation respectively). Using Amaxa, our preliminary data indicate are able to re-program ASC towards the cardiac lineage, based on troponin staining (troponin is an established marker of cardiomyocytes) at an efficiency of ~25%. Will plan to use the Amaxa technology to also deliver the re-programming vector into HSC. Optimization of HSC will commence Aug 2012. We consider this specific task to be ~90% complete as we put significantly more weight on the importance of the experiments using ASC than with HSC, as we ideally prefer to ultimately use ASC in any future therapies since they are more practical to work with. 
Complete all data analysis and draft manuscripts to publish results -15% Complete
The construction of the re-programming vector and preliminary promising data on its potential use to re-program ASC towards the cardiogenic lineage has been reported at the annual ISSCR meeting in Yokohama Japan this summer (Jun 2012).
KEY RESEARCH ACCOMPLISHMENTS:
 Established local IACUC and ACURO approval for planned animal work  Hired and trained a postdoctoral fellow who will perform the majority of the planned work, including cell re-programming and the surgical procedures of induced cardiac infarcts in mice and intra-cardiac transplantation of cells.  Optimized re-programming of ASC towards the cardiogenic lineage, and showed that this process is ~10X more efficient for ASC than HSC.  Completed transplantation of equal numbers of HSC and ASC into mice following induction of infarct, to assess the relative capacity of these cells to facilitate recovery (Task A).
REPORTABLE OUTCOMES:
We have developed a non-viral transposase-based delivery system vector to efficiently deliver re-programming factors, encoded in the vector, into cells, in particular, stem cells. We have also shown that, compared to HSC, ASC may be re-programmed towards the cardiogenic lineage at ~10X the efficiency.
CONCLUSION:
In summary, we believe stem cells, including ASC, hold promise for the development of a new method to treat cardiac infarcts that could potentially enhance the efficiency and degree of recovery of cardiac function. The utility of treatment methods using ASC and derived re-programmed cells also has the capacity to complement other present methods to treat cardiac infarcts (eg. balloon angiograms). Overall, we are on track for accomplishing both tasks for this study by the end of year 2. All proposed work has received the required ACURO and HRPO approval, personnel has been hired and trained, and ASC re-programming towards the cardiogenic lineage has been shown to be successful. In addition, transplantation experiments to test the ability of the ASC and reprogrammed cells to facilitate recovery from induced infarcts have begun. In accordance with the above references, protocol 10214010 entitled, "Therapeutic Evaluation of Hematopoietic Stem Cells for Cardiac Therapy," IACUC protocol number 09-673-3 is approved by the USAMRMC Animal Care and Use Review Office (ACURO) for the use of mice and will remain so until its modification, expiration or cancellation. This protocol was approved by the University of Hawaii, Manoa IACUC.
When updates or changes occur, documentation of the following actions or events must be forwarded immediately to ACURO:  IACUC-approved modifications, suspensions, and triennial reviews of the protocol (All amendments or modifications to previously authorized animal studies must be reviewed and approved by the ACURO prior to initiation.)
 USDA annual program/facility inspection reports CONCLUSIONS AND FUTURE DIRECTIONS •Freshly isolated adipose stromal cells containing hASC have similar lmpacl on heart function and remodeling as HSC-enriched BM (Fig 1.) •hA SC can be transfecled at high efficiency by standard liposomal methods (Fig 28.) •hASC expressing GMT express cardiac·specific proteins wilh sarcom eric s lructure after 14 days of cullure (Fig 3A. ) 1.Delermine differentiation endpoinl for successfully transfected cells.
2 .Co mpare therapeutic efficacy of transfected hASC to nontransfected hASC and freshly isolated adipose stromal cells.
